Mark Forrest Gordon

6.8k total citations
83 papers, 2.6k citations indexed

About

Mark Forrest Gordon is a scholar working on Neurology, Psychiatry and Mental health and Cellular and Molecular Neuroscience. According to data from OpenAlex, Mark Forrest Gordon has authored 83 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Neurology, 33 papers in Psychiatry and Mental health and 19 papers in Cellular and Molecular Neuroscience. Recurrent topics in Mark Forrest Gordon's work include Neurological disorders and treatments (28 papers), Parkinson's Disease Mechanisms and Treatments (20 papers) and Epilepsy research and treatment (14 papers). Mark Forrest Gordon is often cited by papers focused on Neurological disorders and treatments (28 papers), Parkinson's Disease Mechanisms and Treatments (20 papers) and Epilepsy research and treatment (14 papers). Mark Forrest Gordon collaborates with scholars based in United States, Israel and United Kingdom. Mark Forrest Gordon's co-authors include Allison Brashear, Catherine C. Turkel, Andrew Feigin, David Eidelberg, Elie P. Elovic, Christina Marciniak, Mai Do, Thomas Eckert, Steven J. Frucht and Vijay Dhawan and has published in prestigious journals such as New England Journal of Medicine, Journal of the American College of Cardiology and PLoS ONE.

In The Last Decade

Mark Forrest Gordon

78 papers receiving 2.5k citations

Peers

Countries citing papers authored by Mark Forrest Gordon

Since Specialization

Citations

This map shows the geographic impact of Mark Forrest Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Forrest Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Forrest Gordon more than expected).

Fields of papers citing papers by Mark Forrest Gordon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Forrest Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Forrest Gordon. The network helps show where Mark Forrest Gordon may publish in the future.

Co-authorship network of co-authors of Mark Forrest Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Forrest Gordon. A scholar is included among the top collaborators of Mark Forrest Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Forrest Gordon. Mark Forrest Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Trajectories of Pontine Volume in Patients with Multiple System Atrophy 2025 ·Movement Disorders ·Kazuya Kawabata, Florian Krismer, Mizuki Ito, Kazuhiro Hara, Epifanio Bagarinao, Vincent Beliveau, Patrice Péran, (unknown), Anne Pavy‐Le Traon, Wassilios G. Meissner, Alexandra Foubert‐Samier, Margherita Fabbri, Mark Forrest Gordon, Aya Ogura, Masahisa Katsuno, Olivier Rascol, Christoph Scherfler, Klaus Seppi, Hirohisa Watanabe, Werner Poewe	1
2	Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease 2025 ·CNS Drugs ·Samuel Frank, (unknown), Jody Goldstein, Elise Kayson, Blair R. Leavitt, David Oakes, Christine J. O’Neill, Jacquelyn Whaley, Nicholas J. Gross, (unknown), Steve Barash, Mark Forrest Gordon, (unknown)	1
3	Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study 2023 ·Movement Disorders ·Florian Krismer, Patrice Péran, Vincent Beliveau, Klaus Seppi, (unknown), Anne Pavy‐Le Traon, Wassilios G. Meissner, Alexandra Foubert‐Samier, Margherita Fabbri, Michael Schocke, Mark Forrest Gordon, Gregor K. Wenning, Werner Poewe, Olivier Rascol, Christoph Scherfler	12
4	Safety and Efficacy of Long‐Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open‐Label Extension Study 2023 ·Movement Disorders Clinical Practice ·Joseph Jankovic, Barbara J. Coffey, Daniel O. Claassen, Joohi Jimenez‐Shahed, Barry J. Gertz, Elizabeth A. Garofalo, David Stamler, (unknown), Juha‐Matti Savola, (unknown), Jessica Alexander, (unknown), Mark Forrest Gordon	7
5	The effect of potent CYP2D6 inhibition on the pharmacokinetics and safety of deutetrabenazine in healthy volunteers 2021 ·European Journal of Clinical Pharmacology ·(unknown), David Stamler, Margaret Bradbury, Pippa S. Loupe, Mark Forrest Gordon, Laura Rabinovich‐Guilatt	5
6	Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials 2021 ·Frontiers in Neurology ·Kirsi M. Kinnunen, Ariana P. Mullin, Dorian Pustina, Emily C. Turner, Jackson Burton, Mark Forrest Gordon, Rachael I. Scahill, Emily C. Gantman, Simon Noble, Klaus Romero, Nellie Georgiou‐Karistianis, Adam J. Schwarz	4
7	Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case–control study using European electronic health records 2020 ·BMJ Open ·Gayan Perera, Peter R. Rijnbeek, M Alexander, David Ansell, Paul Avillach, Talita Duarte‐Salles, Mark Forrest Gordon, Francesco Lapi, Miguel Ángel Mayer, Alessandro Pasqua, Lars Pedersen, Johan van der Lei, Pieter Jelle Visser, Robert Stewart	11
8	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study 2020 ·The Journals of Gerontology Series B ·Nienke Legdeur, (unknown), Maqsood Yaqub, Nina Beker, Carole H. Sudre, Mara ten Kate, Mark Forrest Gordon, Gerald Novak, Frederik Barkhof, Bart N.M. van Berckel, Henne Holstege, Majon Muller, Philip Scheltens, Andrea B. Maier, Pieter Jelle Visser	18
9	152 Development of Deutetrabenazine as a Potential New Non-Antipsychotic Treatment for Tourette Syndrome in Children and Adolescents 2020 ·CNS Spectrums ·Joseph Jankovic, Barbara J. Coffey, Daniel O. Claassen, David Stamler, Barry J. Gertz, (unknown), (unknown), Mark Forrest Gordon, Juha‐Matti Savola	1
10	Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia (2003) 2020 ·Neurology ·Martha Sajatovic, (unknown), (unknown), (unknown), (unknown), Nicholas J. Gross, Mark Forrest Gordon	1
11	Minimal Clinically Important Difference in AIMS Score Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated With Deutetrabenazine (1916) 2020 ·Neurology ·(unknown), (unknown), (unknown), Mark Forrest Gordon, Robert A. Hauser, Juha‐Matti Savola	0
12	Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients 2017 ·Therapeutic Innovation & Regulatory Science ·Michael T. Ropacki, Kristín Hannesdóttir, Suzanne Hendrix, Mark Forrest Gordon, Diane Stephenson, Stephen Joel Coons, Robert A. Stern	6
13	Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease 2016 ·Parkinson s Disease ·William Seiple, Danna Jennings, Richard B. Rosen, (unknown), (unknown), Nora Fagan, Mark Forrest Gordon	4
14	Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review 2015 ·PLoS ONE ·Eugene Tang, Stephanie L. Harrison, Linda Errington, Mark Forrest Gordon, Pieter Jelle Visser, Gerald Novak, Carole Dufouil, Carol Brayne, Louise Robinson, Lenore J. Launer, Blossom C. M. Stephan	127
15	The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson’s disease: a randomized, double-blind, double-dummy, parallel-group study 2014 ·Translational Neurodegeneration ·Ying Wang, Shenggang Sun, Suiqiang Zhu, Chun‐Feng Liu, Yiming Liu, Qing Di, Huifang Shang, Yan Ren, (unknown), Mark Forrest Gordon, Nolwenn Juhel, Shengdi Chen, (unknown)	13
16	Relationship Between Self-reported Apathy and Executive Dysfunction in Nondemented Patients With Parkinson Disease 2007 ·Cognitive and Behavioral Neurology ·Dennis J. Zgaljardic, Joan C. Borod, Nancy S. Foldi, (unknown), Paul J. Mattis, Mark Forrest Gordon, Andrew Feigin, David Eidelberg	75
17	Effectiveness of Repeated Treatment with Botulinum Toxin Type A Across Different Conditions 2006 ·Southern Medical Journal ·Mark Forrest Gordon, Rich Barron	18
18	Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke 2002 ·New England Journal of Medicine ·Allison Brashear, Mark Forrest Gordon, Elie P. Elovic, (unknown), Christina Marciniak, Mai Do, (unknown), (unknown), Catherine C. Turkel	438
19	Adult-Onset MELAS Presenting as Herpes Encephalitis 1999 ·Archives of Neurology ·(unknown), Mark Forrest Gordon, Richard Libman, (unknown)	31
20	Safety of temporary discontinuation of oral anti-coagulation in pattents with ST.Jude prosthetic valves 1990 ·Journal of the American College of Cardiology ·Irvin F. Goldenberg, Mark Forrest Gordon, (unknown), Wes R. Pedersen, (unknown), James D. Madison, M. Mooney, Fredarick L. Gobel	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact